| 000 | 01144 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250513010806.0 | ||
| 264 | 0 | _c19821202 | |
| 008 | 198212s 0 0 eng d | ||
| 022 | _a0362-5664 | ||
| 024 | 7 |
_a10.1097/00002826-198200051-00007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCalne, D B | |
| 245 | 0 | 0 |
_aThe role of various forms of treatment in the management of Parkinson's disease. _h[electronic resource] |
| 260 |
_bClinical neuropharmacology _c1982 |
||
| 300 |
_aS38-43 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAmantadine _xtherapeutic use |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xdrug therapy |
| 650 | 0 | 4 |
_aErgot Alkaloids _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 |
_aParasympatholytics _xtherapeutic use |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 773 | 0 |
_tClinical neuropharmacology _gvol. 5 Suppl 1 _gp. S38-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00002826-198200051-00007 _zAvailable from publisher's website |
| 999 |
_c7115958 _d7115958 |
||